Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
HPO |
|
|
|
Muscle Weakness
|
0.500 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
An apparently identical deletion in one family gave classical BMD in two brothers (presenting in their teens) and only very mild muscle weakness in their 86-year-old great-great-uncle.
|
2821406 |
1987 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We have previously shown in a large X-linked pedigree that a deletion removing the dystrophin muscle promoter, the first muscle exon and part of intron 1 caused a severe dilated cardiomyopathy with no associated muscle weakness.
|
7635962 |
1995 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We recently described a family where a deletion of the dystrophin gene was associated with a severe dilated cardiomyopathy without skeletal muscle weakness.
|
7825571 |
1995 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
It is speculated that overexpression of the dystrophin-related protein in regenerating muscle fibers may contribute to the slow progression of muscle weakness or atrophy.
|
8352853 |
1993 |
Muscle Weakness
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Ten females presenting with muscle weakness and a raised serum creatine kinase revealed abnormalities in the expression of dystrophin in their muscle biopsies and were diagnosed as manifesting carriers of Xp21 Duchenne/Becker muscular dystrophy.
|
8358239 |
1993 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Each had abnormal dystrophin immunostaining in muscle or cardiac biopsy specimens, but neither had muscle weakness.
|
9470882 |
1997 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Abnormalities of dystrophin are a common cause of muscular dystrophy and testing for dystrophin gene or protein has become a part of routine diagnostic evaluation of patients who present with progressive proximal muscle weakness, high serum creatine kinase concentrations, and histopathological evidence of a dystrophic process.
|
11303236 |
2001 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Somatic mosaicism of a point mutation in the dystrophin gene in a patient presenting with an asymmetrical muscle weakness and contractures.
|
12868501 |
2003 |
Muscle Weakness
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
We report three cases who presented with only mild or no muscle weakness but had elevated serum creatine kinase activity and dystrophin immunolabelling indistinguishable from normal, making a pathological diagnosis difficult.
|
15488030 |
2004 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Associations between clinical phenotype (muscle weakness, dilated cardiomyopathy) and dystrophin abnormalities in muscle tissue among definite carriers of Duchenne (DMD) and Becker muscular dystrophy (BMD) were investigated.
|
16380627 |
2005 |
Muscle Weakness
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
The lack of muscle weakness observed clinically can be explained by expression of the brain and Purkinje dystrophin isoforms in skeletal muscle.
|
17715288 |
2007 |
Muscle Weakness
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
We found that dystrophin levels comprised between 29% and 57% were sufficient to avoid muscle weakness in these XLDC families.
|
17826093 |
2007 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
We report here a case of dystrophinopathy in a 9-years-old boy with a 2-bp deletion in exon 74 of the dystrophin gene; however, the boy had no clear clinical signs of muscle weakness.
|
18430534 |
2009 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations in the DMD gene result in two common phenotypes associated with progressive muscle weakness: the more severe Duchenne muscular dystrophy (DMD) and the milder Becker muscular dystrophy (BMD).
|
19206170 |
2009 |
Muscle Weakness
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Eighteen females showing a mosaic pattern of dystrophin expression on muscle biopsy were recruited and classified as symptomatic (7) or asymptomatic (11), based on the presence or absence of muscle weakness.
|
22894145 |
2012 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Complete loss of muscle dystrophin protein causes progressive muscle weakness and heart and respiratory failure, leading to premature death.
|
23521559 |
2013 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
The absence of dystrophin protein leads to progressive muscle weakness and wasting, disability and death.
|
23784375 |
2013 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Although longer term studies are needed to clarify the relationship between dystrophin restoration following therapeutic intervention and the level of circulating miRNAs, our results indicate that miR-1 and miR-133 can be considered as exploratory biomarkers for monitoring the progression of muscle weakness and indirectly the remaining muscle mass in DMD.
|
24282529 |
2013 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weakness caused by DMD gene mutations leading to absence of the full-length dystrophin protein in muscle.
|
25043804 |
2014 |
Muscle Weakness
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
Duchenne muscular dystrophy (DMD) is a genetic, lethal, muscle disorder caused by the loss of the muscle protein, dystrophin, leading to progressive loss of muscle fibers and muscle weakness.
|
25975656 |
2015 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle.
|
26457695 |
2015 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
|
26930420 |
2016 |
Muscle Weakness
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
For the last 20 years, the major goal in the development of therapeutic approaches to alleviate muscle weakness in DMD has been centered on the restoration of dystrophin or proteins that are analogous to dystrophin, such as utrophin, through a variety of modalities including cell therapy, gene therapy, gene correction, and the highly promising techniques utilizing CRISPR/Cas9 technology.
|
27071500 |
2016 |